BOARD OF DIRECTORS

Vince Burgess

Executive Chairman

Mr. Burgess is a Venture Partner at OrbiMed Advisors LLC with over 20 years experience in healthcare operations, business development and venture capital. Vince was on the founding executive team at Volcano Corp., serving as Group President, Advanced Imaging Systems. During his tenure, Volcano grew from a raw start-up to a global company with market cap of over $1.2 billion. Previously, Mr. Burgess served as a general partner of San Diego-based Sorrento Ventures, focusing on healthcare investments.

David P. Bonita, M.D.

Director

Dr. Bonita is a Private Equity Partner at OrbiMed Advisors LLC. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School.

Nissim Darvish, M.D., Ph.D.

Director

Dr. Darvish is a Senior Managing Director at OrbiMed. He has more than 15 years of experience in the life science industry, covering medical technology development, corporate leadership and investment management. Dr. Darvish spent eight years with Pitango, where he was a General Partner managing life science investments. Previously, he was the founder and CEO of Impulse Dynamics.

Chris Richardson

Director

Mr. Richardson has spent his 25-year career taking cardiac startup companies from the clinical trial phase through worldwide commercialization and into acquisition. Prior to joining Keystone Heart, Richardson was international president and CCO of Direct Flow Medical, a transcatheter aortic valve company, and general manager, Abbott Vascular Structural Heart, a global company focused on percutaneous mitral valve repair, which Richardson joined through its acquisition of Evalve. Chris has also held leadership positions at Boston Scientific’s Cardiac Rhythm Management business and GSC Management Development at Guidant, Heartport (acquired by Johnson & Johnson) and Devices for Vascular Intervention (acquired by Guidant).

Mark Maciejewski

Director

Experienced VC and Private Equity within the global community (US, China, Europe and Middle East), and long standing public and private Life Science Company’s relationships. Experience with investment model in “Cross Boarder Transaction” between China (listed and private PRC companies) and USA entities. Specialized in Joint Venture formation and transactions. Experienced CEO level executive from large multi-national medical device firms to small venture backed start-up. Includes experience in USA, Europe, Asia and the Middle East. Founded, formed and funded such early stage companies such as; AngioGuard, Devax, Symphony Medical, Suturtek, Celleration, RegenRX and Venus MedTech. Broad Operational experience through haven take multiple companies from concept to company formation, funding, major milestones and exit on order to support portfolio companies.